BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND PRKACA, MGC48865, 5566, ENSG00000072062, P17612, PKACA, MGC102831
59 results:

  • 1. Anti-Tumor Activity and Mechanism of Silibinin Based on Network Pharmacology and Experimental Verification.
    Li P; Wang D; Yang X; Liu C; Li X; Zhang X; Liu K; Zhang Y; Zhang M; Wang C; Wang R
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675723
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. DNAJB1-prkaca fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
    Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
    PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. DNAJB1-prkaca fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
    Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
    Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. GalNAc-conjugated siRNA targeting the DNAJB1-prkaca fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.
    Du L; Wilson BAP; Li N; Shah R; Dalilian M; Wang D; Smith EA; Wamiru A; Goncharova EI; Zhang P; O'Keefe BR
    J Nat Prod; 2023 Oct; 86(10):2283-2293. PubMed ID: 37843072
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
    Kim J; Kim Y; Lee B
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation.
    Qiao X; Lin J; Shen J; Chen Y; Zheng L; Ren H; Zhao X; Yang H; Li P; Wang Z
    Oncogene; 2023 Sep; 42(39):2878-2891. PubMed ID: 37596321
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
    Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
    Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. An Unusual Case of Hepatocellular Carcinoma in a Healthy Teenager.
    Ugonabo O; Pulipati Y; Elghezewi A; Miller V; Logan L; Pramod P
    J Investig Med High Impact Case Rep; 2023; 11():23247096231165744. PubMed ID: 37119001
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The oncogenic fusion protein DNAJB1-prkaca can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
    Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
    Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-prkaca.
    Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
    Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (prkaca) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
    Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
    Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Use of Fluorescence
    Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
    Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Successful liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
    Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
    Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. LncRNA THEMIS2-211, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA.
    Yao J; Hua X; Shi J; Hu X; Lui K; He K; Mai J; Lan T; Lu M
    FASEB J; 2022 Apr; 36(4):e22238. PubMed ID: 35224785
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A framework for fibrolamellar carcinoma research and clinical trials.
    Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
    Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. DNAJB1-prkaca in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
    Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
    PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (
    Karamafrooz A; Brennan J; Thomas DD; Parker LL
    J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.